Listeners:
Top listeners:
play_arrow
Radio Today Radio Today
play_arrow
Rocking Today Rocking Down the Highway
Radio Today News Mike Stroud
Radio Today News Mike Stroud
Prostate cancer develops in the prostate, an organ just below the urethra that is an essential part of the male reproductive system. Most prostate cancers do not have an identifiable cause, but doctors have found many factors that raise the risk of developing the disease. Prostate cancer is the fourth most prevalent cancer in the world, with 1.27 million cases diagnosed in 2018.
Excess WeightÂ
A significant number of people diagnosed with prostate cancer are overweight. Doctors use an objective measure called body mass index (BMI) to determine if a person is a healthy weight, overweight, or obese. Individuals with a BMI of between 25 and 30 are classified as overweight, while a BMI of more than 30 is considered obese. Being overweight only slightly increases the risk of prostate cancer, while obesity substantially raises the risk.
Urinary ProblemsÂ
Urinary issues usually begin once the tumour has grown large enough to put pressure on the urethra, the tube that carries urine from the bladder, through the penis. Many men report an urgent need to urinate, especially at night, but when they try to urinate, they have difficulty starting the stream. Others experience a slow, weak, or interrupted stream of urine, and dribbling afterwards. Incontinence can also develop, as can pain or burning during urination. Hematuria or blood in the urine is also a possible symptom. Some men experience frequent urinary tract infections. However, urination issues do not always indicate prostate cancer; they may be symptoms of other conditions.
What is stereotactic body radiation therapy?
Stereotactic body radiation therapy administers radiotherapy from several different points around the body, with the radiation beams meeting at the spot of the tumour. The tumour receives a very high dose of radiation, while surrounding tissue receives less, lowering the risk of side effects and complications.
SBRT is used for a number of cancers, including prostate cancer, early-stage lung cancer, pancreatic cancer and some brain tumours. It is also used for cancers that have spread or metastasized to the lung/s, liver, brain, spine, bones or adrenal gland.
How does stereotactic body radiation therapy work?
SBRT is a non-invasive form of radiation treatment that involves high-dose radiation beams. It can deliver precisely targeted radiation in fewer high-dose treatments than traditional radiation therapy, which reduces the total amount of radiation to healthy tissue. SBRT requires advanced radiation technology.
Beating prostate cancer without surgery – A success story
A patient was unable to receive standard therapy for prostate cancer. SBRT made it possible for him to get the treatment he needed in less time.
The following details explain why.
Benefits and risks of stereotactic body radiation therapy SBRT offers many advantages, including:
Conventional radiation is typically delivered in small doses daily over many weeks. This can delay or interfere with other cancer treatments, such as chemotherapy. Many weeks of daily radiation treatment can significantly disrupt a patient’s life, including work. By contrast, SBRT can usually be given in 5 or fewer treatments.
SBRT using advanced radiation technology also can lead to better outcomes and fewer side effects than conventional radiation therapy.
For prostate cancer, advanced SBRT reduces radiation treatment from 9 weeks to 1 week, and results in excellent long-term outcomes in terms of cure and quality of life. Physicians at The University of Kansas Cancer Centre were among the first in the America to develop this advanced treatment for prostate cancer more than 10 years ago.
https://facty.com/conditions/cancer/10-causes-of-prostate-cancer/
Scientists are testing new drug molecules to develop treatments for Parkinson’s. Researchers at McGill University in Montreal, Quebec, have found that a novel drug molecule may have the ability to fight the development of early-onset Parkinson’s disease in younger people, according to a new study published in Nature Communications. The new compound is […]
Post comments (0)